VTRS News and Press, Viatris Inc. From 07/31/23

Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva PR Newswire Lau...

2023-07-29 01:40:00 ET Summary Dividend investing happens, whether the stock market is up or down, whether the Fed raises interest rates or lowers. The stock market, specifically the S&P 500, is back above 4,500. I own each stock and am constantly evaluating the stock mark...

2023-07-26 16:27:28 ET Summary The Fed raised rates by 25 bps, as widely expected. Impact on high-yield S&P 500 stocks discussed. S&P 500 at 4,700 assessed. Expectations of 2% inflation in 2025 at the earliest discussed. The Federal Reserve raised interest ra...

2023-07-22 06:00:00 ET Even if you don't recognize the name Viatris (NASDAQ: VTRS) , you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec allergy pills -- as well as branded medicines like cholesterol dr...

2023-07-20 09:20:00 ET A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and investors shouldn't assume they won't change or suddenly stop. Plus, it's...

2023-07-19 14:00:00 ET Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their share performance paths have diverged. Pfizer stock so...

2023-07-18 10:47:52 ET Summary Viatris is a global healthcare company focused on improving access to high-quality healthcare worldwide. Q1 2023 earnings showed a 2% decrease in net sales, with notable performers and exceeded expectations in generics. Viatris stock presents mix...

2023-07-18 00:28:43 ET Summary Viatris Inc. has a low valuation with a forward P/E of under 4 and a market cap of over $12 billion, predicted to reach $15.75 billion in revenues by 2023. The company recently acquired Oyster Point Pharma and Famy Life Sciences, expanding its exposu...

2023-07-15 17:00:00 ET If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS) . Both companies offer attractive dividend yields of 8.3% and 4.7%, respectively, as of July 14. But whi...

2023-07-14 20:15:00 ET Summary The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. Looking back at my June totals, I see that my year-over-year progress ...